Should I buy or sell Extendicare stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Extendicare in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EXE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EXE, but not buy additional shares or sell existing shares. View EXE analyst ratings or view top-rated stocks .

What is Extendicare's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price targets for Extendicare's stock. Their EXE share price targets range from C$7.50 to C$8.50. On average, they expect the company's share price to reach C$7.88 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View analysts price targets for EXE or view top-rated stocks among Wall Street analysts .

How have EXE shares performed in 2024?

Extendicare's stock was trading at C$7.28 at the beginning of the year. Since then, EXE shares have decreased by 0.3% and is now trading at C$7.26. View the best growth stocks for 2024 here .

When is Extendicare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our EXE earnings forecast .

How were Extendicare's earnings last quarter?

Extendicare Inc. (TSE:EXE) announced its quarterly earnings results on Thursday, March, 7th. The company reported $0.10 EPS for the quarter. Extendicare had a trailing twelve-month return on equity of 36.03% and a net margin of 2.60%.

How often does Extendicare pay dividends? What is the dividend yield for Extendicare?

Extendicare announced a monthly dividend on Monday, April 15th. Shareholders of record on Tuesday, April 30th will be given a dividend of 0.04 per share on Wednesday, May 15th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date of this dividend is Monday, April 29th. Read our dividend analysis for EXE .

Is Extendicare a good dividend stock?

Extendicare (TSE:EXE) pays an annual dividend of C$0.48 per share and currently has a dividend yield of 6.49%. EXE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 120.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for EXE .

What other stocks do shareholders of Extendicare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Extendicare investors own include Inter Pipeline (IPL) , Pembina Pipeline (PPL) , BCE (BCE) , Chorus Aviation (CHR) , Cenovus Energy (CVE) , Medical Facilities (DR) , Martinrea International (MRE) , Air Canada (AC) , AltaGas (ALA) and Emera (EMA) .

How do I buy shares of Extendicare?

Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:EXE

Extendicare (EXE) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free EXE Stock Alerts

C$7.26

+0.02 (+0.28%)

(As of 05:22 PM ET)

Compare

Today's Range: C$7.20
▼
C$7.28
50-Day Range: C$6.65
▼
C$7.88
52-Week Range: C$5.75
▼
C$7.90

Volume: 103,960 shs
Average Volume: 122,226 shs
Market Capitalization: C$603.74 million

P/E Ratio: 18.15
Dividend Yield: 6.61%
Price Target: C$7.88

Stock Analysis Analyst Forecasts Chart Competitors Dividend Earnings Headlines

Get Extendicare alerts:

Extendicare MarketRank™ Stock Analysis

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 8.5% Upside
C$7.88 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.53
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.51 out of 5 stars

1.2

Analyst's Opinion

Consensus Rating
Extendicare has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Extendicare has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for EXE.

1.7

Dividend Strength

Dividend Leadership
Extendicare is a leading dividend payer. It pays a dividend yield of 6.49%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Extendicare does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Extendicare is 120.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EXE.

2.5

News and Social Media Coverage

News Sentiment
Extendicare has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Extendicare this week, compared to 1 article on an average week.
Search Interest
3 people have searched for EXE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Extendicare insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.61% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.18% of the stock of Extendicare is held by institutions.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Extendicare is 18.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of Extendicare is 18.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.
Price to Book Value per Share Ratio
Extendicare has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

About Extendicare Stock (TSE:EXE)

Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties. It operates through the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada.

EXE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EXE Stock News Headlines

April 12, 2024 | americanbankingnews.com

Extendicare (TSE:EXE) Stock Crosses Above Two Hundred Day Moving Average of $6.86

April 9, 2024 | theglobeandmail.com

Contra Guys: As seniors’ population rises, Extendicare worth a look

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 8, 2024 | finance.yahoo.com

Can Extendicare Inc. (TSE:EXE) Maintain Its Strong Returns?

April 4, 2024 | theglobeandmail.com

Extendicare Announces Timing of 2024 First Quarter Results and Conference Call

April 4, 2024 | finance.yahoo.com

Extendicare Announces Timing of 2024 First Quarter Results and Conference Call

March 20, 2024 | fool.ca

Invest $374.50 Each Month to Create Passive Income of $288 in 2024

March 10, 2024 | seekingalpha.com

Extendicare Inc. (EXETF) Q4 2023 Earnings Call Transcript

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 8, 2024 | finanznachrichten.de

Extendicare Inc: Extendicare Announces 2023 Fourth Quarter and Year End Results

March 8, 2024 | msn.com

Extendicare GAAP EPS of C$0.10, revenue of C$350.18M

February 20, 2024 | finance.yahoo.com

Is Now An Opportune Moment To Examine Extendicare Inc. (TSE:EXE)?

February 15, 2024 | finance.yahoo.com

Extendicare Opens the Market

January 19, 2024 | finance.yahoo.com

Extendicare Announces Timing of 2023 Fourth Quarter Results and Conference Call

January 15, 2024 | finance.yahoo.com

Extendicare Announces January 2024 Dividend of C$0.04 per Share

December 23, 2023 | seekingalpha.com

EXE:CA Extendicare Inc.

December 15, 2023 | finance.yahoo.com

Extendicare Announces December 2023 Dividend of C$0.04 per Share

November 9, 2023 | finance.yahoo.com

Extendicare Announces 2023 Third Quarter Results

October 19, 2023 | theglobeandmail.com

Closing Bell: Extendicare Inc flat on Thursday (EXE)

October 16, 2023 | finance.yahoo.com

Extendicare Announces October 2023 Dividend of C$0.04 per Share

October 11, 2023 | finance.yahoo.com

Extendicare Inc.'s (TSE:EXE) Intrinsic Value Is Potentially 61% Above Its Share Price

September 15, 2023 | finance.yahoo.com

Extendicare Announces September 2023 Dividend of C$0.04 per Share

September 14, 2023 | finanznachrichten.de

Extendicare Inc: Extendicare Announces Closing of Transaction with Axium

September 14, 2023 | finance.yahoo.com

EXE.TO - Extendicare Inc.

September 13, 2023 | theglobeandmail.com

Closing Bell: Extendicare Inc 5 Pct Debs down on Wednesday (EXE-DB-C)

September 13, 2023 | finance.yahoo.com

Extendicare Announces Closing of Transaction with Axium

August 28, 2023 | theglobeandmail.com

Closing Bell: Extendicare Inc flat on Monday (EXE)

See More Headlines

Receive EXE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Ex-Dividend for 4/15 Dividend: 3/27/2024
Dividend Payable: 4/15/2024
Today: 4/19/2024
Ex-Dividend for 5/15 Dividend: 4/29/2024
Dividend Payable: 5/15/2024
Next Earnings (Confirmed): 5/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Medical Care Facilities
Sub-Industry: N/A
Current Symbol: TSE:EXE
CUSIP: N/A
CIK: N/A
Web: www.extendicare.com
Phone: 905-470-4000
Fax: N/A
Employees: 23,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$7.88
High Stock Price Target: C$8.50
Low Stock Price Target: C$7.50
Potential Upside/Downside: +8.5%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): C$0.40
Trailing P/E Ratio: 18.15
Forward P/E Ratio: 18.82
P/E Growth: N/A
Net Income: C$33.98 million
Net Margins: 2.60%
Pretax Margin: N/A
Return on Equity: 36.03%
Return on Assets: 6.84%

Debt

Debt-to-Equity Ratio: 380.48
Current Ratio: 0.83
Quick Ratio: 0.98

Sales & Book Value

Annual Sales: C$1.30 billion
Price / Sales: 0.46
Cash Flow: C$2.27 per share
Price / Cash Flow: 3.20
Book Value: C$1.06 per share
Price / Book: 6.85

Miscellaneous

Outstanding Shares: 83,160,000
Free Float: N/A
Market Cap: C$603.74 million
Optionable: Not Optionable
Beta: 1.22

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Michael R. Guerriere M.D. (Age 60)
MBA, CEO, President & Director
Comp: $1.11M
Mr. David E. Bacon
Senior VP & CFO
Mr. John Toffoletto
Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Matthew Morgan
Chief Medical Officer
Mr. Steve Paraskevopoulos
Senior Vice President of ParaMed & CTO
Joe Belinsky
VP of Information Technology & Chief Information Officer
Ms. Jillian E. Fountain
Vice President of Investor Relations
Ms. Kathryn Killoran Bradley
Vice President of Corporate Development
Ms. Katie LeMoyne
Senior VP & Chief HR Officer
Ms. Wendy Gilmour
Senior VP of LTC Operations

Key Competitors

View All Competitors

EXE Stock Analysis - Frequently Asked Questions

Should I buy or sell Extendicare stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Extendicare in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EXE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EXE, but not buy additional shares or sell existing shares.
View EXE analyst ratings or view top-rated stocks.
What is Extendicare's stock price target for 2024?: 5 Wall Street analysts have issued twelve-month price targets for Extendicare's stock. Their EXE share price targets range from C$7.50 to C$8.50. On average, they expect the company's share price to reach C$7.88 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts price targets for EXE or view top-rated stocks among Wall Street analysts.
How have EXE shares performed in 2024?: Extendicare's stock was trading at C$7.28 at the beginning of the year. Since then, EXE shares have decreased by 0.3% and is now trading at C$7.26.
View the best growth stocks for 2024 here.
When is Extendicare's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our EXE earnings forecast.
How were Extendicare's earnings last quarter?: Extendicare Inc. (TSE:EXE) announced its quarterly earnings results on Thursday, March, 7th. The company reported $0.10 EPS for the quarter. Extendicare had a trailing twelve-month return on equity of 36.03% and a net margin of 2.60%.

How often does Extendicare pay dividends? What is the dividend yield for Extendicare?: Extendicare announced a monthly dividend on Monday, April 15th. Shareholders of record on Tuesday, April 30th will be given a dividend of 0.04 per share on Wednesday, May 15th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date of this dividend is Monday, April 29th.
Read our dividend analysis for EXE.
Is Extendicare a good dividend stock?: Extendicare (TSE:EXE) pays an annual dividend of C$0.48 per share and currently has a dividend yield of 6.49%. EXE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 120.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for EXE.
What other stocks do shareholders of Extendicare own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Extendicare investors own include Inter Pipeline (IPL), Pembina Pipeline (PPL), BCE (BCE), Chorus Aviation (CHR), Cenovus Energy (CVE), Medical Facilities (DR), Martinrea International (MRE), Air Canada (AC), AltaGas (ALA) and Emera (EMA).
How do I buy shares of Extendicare?: Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:EXE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Extendicare (EXE) Stock Price, News & Analysis

Extendicare MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Extendicare Stock (TSE:EXE)

EXE Stock Price History

EXE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EXE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™